The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life ...

The UK government will contribute up to £50 million of new investment into the scheme, with Lilly contributing up to £35 ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...

We assume that what worked in the 1950s still works now. We assume that more budget is the only answer. Yet, AI can help in ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...